biotech
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.
Published:
Inovio Pharmaceuticals shares soared on Monday after the company provided an update for its coronavirus vaccine candidate.
Published:
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Published:
Five Prime Therapeutics' shares more than tripled on Wednesday after the company announced positive topline results from its gastric cancer study.
Published:
Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Published:
24/7 Wall St. has tracked multiple analyst calls regarding the expected approval or nonapproval of aducanumab as the first viable treatment against Alzheimer's disease.
Published:
Pfizer and BioNTech stocks both exploded on Monday after these companies provided an update on their coronavirus vaccine.
Published:
Regeneron Pharma reported its third-quarter financial results before the markets opened on Thursday.
Published:
Biogen shares rocketed up on Wednesday after briefing documents from the FDA provided evidence of the effectiveness of the firm’s Alzheimer’s disease treatment.
Published:
Aurinia Pharma shares slid on Tuesday after the company reported results from its midstage study for the treatment of dry eye syndrome.
Published:
DBV Technologies is making a comeback after making headway for its peanut allergy treatment in Europe.
Published:
Equillium shares jumped on Friday after the company announced a key update from the FDA regarding its late-stage COVID-19 trial.
Published:
When Moderna reported its most recent quarterly results before the markets opened on Thursday, the earnings (or loss in this case) were not the most important feature of the report.
Published: